In summary, given the pivotal role of NLRP3 inflammasome activation in diverse inflammatory and autoimmune disorders, and considering LMT2368’s efficacy and improved pharmacological profile demonstrated in vitro and in vivo, this compound holds promise as a lead candidate for therapeutic development. This evidence concerns the gene NLRP3 and Autoimmunity.